Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), IQVIA Holdings (IQV) and Ascendis Pharma (ASND)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Elanco Animal Health (ELAN – Research Report), IQVIA Holdings (IQV – Research Report) and Ascendis Pharma (ASND – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Elanco Animal Health (ELAN)
In a report issued on January 2, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Elanco Animal Health, with a price target of $27.00. The company’s shares closed last Friday at $22.52.
According to TipRanks.com, Block is a 4-star analyst with an average return of
Elanco Animal Health has an analyst consensus of Strong Buy, with a price target consensus of $25.36.
See the top stocks recommended by analysts >>
IQVIA Holdings (IQV)
Citi analyst Patrick B Donnelly maintained a Hold rating on IQVIA Holdings today. The company’s shares closed last Friday at $225.37.
According to TipRanks.com, Donnelly is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings with a $250.58 average price target.
Ascendis Pharma (ASND)
In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Ascendis Pharma, with a price target of $250.00. The company’s shares closed last Friday at $213.29.
According to TipRanks.com, Skor is a 5-star analyst with an average return of
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $263.42.
